Scott Turner
Company: Pliant Therapeutics Inc.
Job title: Senior Vice President , Research
Seminars:
The Road to Success: Selectively Targeting TGF-β for Antifibrotic Drug Development & Harnessing the Translational Insights for Immuno-Oncology 9:00 am
Highlighting the discovery and development of PLN-74809, a dual selective integrin inhibitor for pulmonary fibrosis Uncovering Pliant’s translational approach and successful Phase 2 results in IPF Reprogramming the tumor microenvironment with selective inhibition of TGF-β Discussing blocking integrin activation of TGF-β to increase checkpoint inhibitor efficacy and targeting immune and stromal activation of TGF-βRead more
day: Day One
Discussion Panel: Forecasting the Future Developments in Targeting TGF-β for Immuno-Oncology: Where May the Next 3-5 Years Take Us? 12:00 pm
day: Day One